136 related articles for article (PubMed ID: 22101248)
1. Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Liu Y; Qu X
Mol Med Rep; 2012 Feb; 5(2):580-4. PubMed ID: 22101248
[TBL] [Abstract][Full Text] [Related]
2. RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Oncol Rep; 2011 Nov; 26(5):1243-50. PubMed ID: 21725611
[TBL] [Abstract][Full Text] [Related]
3. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
[TBL] [Abstract][Full Text] [Related]
5. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
6. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
7. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
9. BU-32: a novel proteasome inhibitor for breast cancer.
Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
[TBL] [Abstract][Full Text] [Related]
12. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
13. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
[TBL] [Abstract][Full Text] [Related]
14. C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
Oncol Lett; 2012 Feb; 3(2):395-400. PubMed ID: 22740919
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
16. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
17. Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer.
Wang J; Liu Y; Wang L; Sun X; Wang Y
Oncotarget; 2016 Feb; 7(5):5564-75. PubMed ID: 26734994
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits human osteoclastogenesis.
von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
20. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
